...p<0.004) vs. vehicle. Sofpironium bromide was well tolerated with no treatment-related serious adverse events reported. Kaken Pharmaceutical Co. Ltd....
...from Brickell to develop and commercialize the topical soft anticholinergic. Brickell Biotech Inc., Boulder, Colo. Kaken Pharmaceutical Co. Ltd....

...Numab Therapeutics AG (Pfaeffikon, Switzerland) and Kaken Pharmaceutical Co. Ltd. (Tokyo:4521) partnered to identify a multi-specific antibody candidate for...
...platform. Under the deal, Kaken will fund Numab’s efforts to identify a multi-specific antibody candidate. Kaken...
...disclose additional details. Numab Therapeutics AG , Pfaeffikon, Switzerland Kaken Pharmaceutical Co. Ltd. (Tokyo:4521), Tokyo, Japan Business: Inflammatory Julian Zhu Kaken Pharmaceutical Co. Ltd. Numab...

...outcome measure, the Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax), vs. vehicle. BBI-4000 was well tolerated. Kaken...
...Asian countries from Brickell to develop and commercialize BBI-4000. Brickell Biotech Inc. , Miami, Fla. Kaken Pharmaceutical Co. Ltd....

...and South Korea, to the topical triazole antifungal from Kaken (see BioCentury, May 20, 2013). Kaken Pharmaceutical Co. Ltd....

...DEL1 ; EDIL3 ). 8,9 However, Takuro Yuge, senior manager of R&D strategic planning at Kaken Pharmaceutical Co. Ltd....
...bone deterioration," said Katsumi Nogimori, Kaken's executive corporate officer and deputy chief officer of R&D. Kaken's...
...Haas, M.J. SciBX 6 (45); doi:10.1038/scibx.2013.1281 Published online Nov. 21, 2013 Companies and Institutions Mentioned Kaken Pharmaceutical Co. Ltd....

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....

...Valeant has worldwide commercialization rights, excluding Japan, China, Taiwan and South Korea, to efinaconazole from Kaken...
...hear from the judge in the case "in a few weeks" (see BioCentury, May 20). Kaken Pharmaceutical Co. Ltd....

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken...
...fiduciary duty, intentional interference with prospective business advantage and unfair competition (see BioCentury, May 20). Kaken Pharmaceutical Co. Ltd....

...commercialization rights, excluding Japan, China, Taiwan and South Korea, to the topical triazole antifungal from Kaken Pharmaceutical Co. Ltd....